Abstract
Immunotherapies have revolutionized the standard-of-care cancer treatment and engineered T-cell therapy has been approved for treating certain tumor types. However, tumor-mediated immunosuppression still represents a major obstacle to these approaches. Dying tumor cells release substantial amounts of intracellular K+, causing 10-15-fold increased concentrations of extracellular K+ ([K+]e). Tumor-infiltrating lymphocytes bathed in this [K+]e-rich fluid are suppressed. Here, we investigated the impact of high-[K+]e on human T-cell functions.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
